Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through video calls and online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
In the United States new drugs are tested in clinical trials (research studies) before they are approved by the US Food and Drug Administration (FDA) for use in the general public. The clinical trials are done to show that the drug:
When the FDA is satisfied that the drug works and is safe, it and the maker of the drug create the drug label. This is not an actual label that sticks to a bottle, but a report of very specific information about the drug. The FDA must approve this report, which is made available to all health professionals who prescribe or sell the drug.
The drug label gives information about the drug, including the specific medical condition(s) it’s approved for (called the indication(s) for use), the doses to be used, and how it’s to be given. When a drug is used in a way that is different from that described in the FDA-approved drug label, it’s said to be an “off-label” use. This can mean that the drug is:
For example, when a chemotherapy drug is approved for treating one type of cancer but is used to treat a different cancer, it’s off-label use. The same is true if a drug is approved to treat a type of cancer at a specific stage (extent of spread), but it is used to treat a cancer at a different stage.
Off-label is also called non-approved or unapproved use of a drug.
The off-label use of FDA-approved drugs is not regulated, but it is legal in the United States and many other countries. An exception to this is the use of some controlled substances, such as opioids (pain medicines like morphine and fentanyl). These drugs cannot legally be prescribed in the United States except for approved purposes.
While it’s legal for doctors to use drugs off label, it’s not legal for drug companies to market (advertise or promote) their drugs for off-label uses. Off-label marketing is very different from off-label use.
Older, generic (non-brand name) medicines are the ones most often used off label. New uses for these drugs may have been found and there’s often medical evidence from research studies to support the new use. But it’s often too costly for the makers of the drugs to put them through the formal, lengthy, and expensive process required by the FDA to officially approve the drug for new uses.
Off-label drug use is common in cancer treatment because:
The biggest problem is getting insurance plans to pay (reimburse) for off-label drug use. Many insurance companies will not pay for an expensive drug that’s used in a way that’s not listed in the approved drug label. They do this on the grounds that its use is “experimental” or “investigational.”
In cancer treatment, these issues have been largely addressed through 1993 federal legislation that requires insurance to cover medically appropriate cancer therapies. This law includes off-label uses if the treatment has been tested in careful research studies and written up in well-respected drug reference books or medical journals. In 2008, Medicare rules were changed to cover more off-label uses of cancer treatment drugs.
Still, the health insurance coverage laws and regulations are complex. If your doctor is thinking about off-label drug use, you and your doctor should carefully check your health plan’s coverage. If you are denied coverage, it might help if the doctor sends the insurer copies of peer-reviewed journal articles or other respected sources that support the off-label use.
Another problem is that off-label drug use often does not reflect “standard of care” treatment. This could raise concerns about the legal risk to the health care provider should a patient have an unwanted or bad outcome from the treatment.
The FDA does not regulate the practice of medicine. In general, once the FDA approves a drug, licensed doctors can use it for any purpose they consider medically appropriate.
One of the biggest problems related to widespread off-label use is the lack of information about how to best use the drug other than for what it was approved. The drug label is one of the most reliable and easy-to-find sources of information available to health professionals, caregivers, and patients. But the label can only contain the information that’s been approved by the FDA, and it does not cover off-label uses.
The medical literature reports clinical trials, including those that are not part of the FDA approval process. This is the main source of off-label use information. Some professional health organizations develop treatment guidelines that may offer options including off-label drug uses. Treatment guidelines are based on information from medical literature, including clinical trials, and recommend standard ways to treat certain diseases.
Lack of information on off-label drug use and outcomes may also put patients at a higher risk for medication errors, side effects, and unwanted drug reactions. It’s important that the patient and doctor talk about the possible risks of using the drug and weigh them against the possible benefits.
Little information is available on off-label prescribing in oncology in the US. Off-label use can vary greatly from one doctor to another, depending on doctors’ preferences, knowledge, and past patient experiences. A 2008 study found that 8 out of 10 cancer doctors surveyed had prescribed drugs off-label. Off-label drug use is also well-documented and very common in certain other settings, such as in pediatrics and HIV/AIDS care.
Studies have reported that about half of the chemotherapy drugs used are given for conditions not listed on the FDA-approved drug label. In fact, the National Cancer Institute (NCI) has stated, “Frequently the standard of care for a particular type or stage of cancer involves the off-label use of one or more drugs.”
Actual off-label use might be even higher than what has been reported.
Chemotherapy and other cancer treatment drugs (such as hormone therapy, immunotherapy, and targeted therapy drugs) can be used off label, but so can some other drugs used during the course of cancer treatment.
Treating certain types of pain with tricyclic antidepressants is an example of off-label drug use. This old class of drugs is approved and labeled to be used for clinical depression. Today these drugs are seldom used to treat depression because safer drugs are available. But doctors have found that the tricyclics often work very well in treating certain types of pain.
Another example is lorazepam (Ativan®), an anti-anxiety drug that is often used as an anti-nausea drug in cancer treatment. In oncology, lorazepam is most commonly given under the tongue (the sublingual route), which is also not listed on the drug label. In this case, it’s being given for an off-label use and by an off-label route.
Here are some questions you might want to ask your doctor. Start by asking if all the drugs recommended for your cancer treatment are approved for the planned use. If any of the drugs are not, you can ask:
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Along with the American Cancer Society, other sources of information and support include:
National Cancer Institute
Toll-free number: 1-800-422-6237 (1-800-4-CANCER)
Provides accurate, up-to-date information about cancer to patients, their families, and the general public, also has a free clinical trials matching service
US Food and Drug Administration, Center for Drug Evaluation and Research
Toll-free number: 1-888-463-6332
Offers information about approved drugs, but cannot discuss drugs under investigation unless the company making the drug has published material on that drug. Will provide contact information for drug companies if callers know the name of the company.
*Inclusion on this list does not imply endorsement by the American Cancer Society.
American Society of Clinical Oncology. Reimbursement for cancer treatment: Coverage of off-label drug indications. J Clin Oncol. 2006;24:3206-3208.
Conti RM, Bernstein AC, Villaflor VM, et al. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol. 2013;31:1134-1139.
Fairman KA, Curtiss FR. Regulatory actions on the off-label use of prescription drugs: Ongoing controversy and contradiction in 2009 and 2010. JMCP. 2010;16:629-639.
Kocs D, Fendrick AM. Effect of off-label use of oncology drugs on pharmaceutical costs: The rituximab experience. Am J Manag Care. 2003;9:393-402.
Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: Evidence and ethical off-label prescribing. Arch Intern Med. 2009;169:1745-1747.
Mortenson LE. The off-label debate: A threat to the future of cancer care. Cancer Invest. 1991;9:597-599.
National Cancer Institute. Off-Label Drug Use in Cancer Treatment. 2014. Accessed at www.cancer.gov/cancertopics/druginfo/offlabeldrug on March 17, 2015.
Peppercorn J, Burstein H, Miller FG, Winer E, Joffe S. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008;26(36):5994-6000.
Poole SG, Dooley MJ. Off-label prescribing in oncology. Support Care Cancer. 2004;12:302-305.
Thakkar S. Oncologists judge themselves the best judges of cancer treatments. J Natl Cancer Inst. 1997;89:1188-1189.
United States General Accounting Office. Off-label drugs, reimbursement policies constrain physicians in their choice of cancer therapies (report GAO/PEMD-91-14). September 1991. Washington DC. Accessed at http://archive.gao.gov/d18t9/144933.pdf on March 17, 2015.
Last Revised: March 17, 2015